Ultracet - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:45Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Opioid analgesics]]
			[[Category:Non-opioid analgesics]]
			[[Category:Schedule IV controlled substances]]
			[[Category:Fixed-dose combinations]]
			[[Category:SNRIs]]

MDElliottMD: home-claude house-rule fix (terminology)

2026-05-23T04:50:58Z

home-claude house-rule fix (terminology)

← Older revision		Revision as of 04:50, 23 May 2026
Line 16:		Line 16:
	\| pregnancy = Avoid; neonatal opioid withdrawal documented.{{citation needed}}		\| pregnancy = Avoid; neonatal opioid withdrawal documented.{{citation needed}}
	\| legal = [[USLegal:Schedule IV\|Schedule IV controlled substance]] in US (tramadol was reclassified from non-controlled to Schedule IV in 2014 after recognition of dependence risk)		\| legal = [[USLegal:Schedule IV\|Schedule IV controlled substance]] in US (tramadol was reclassified from non-controlled to Schedule IV in 2014 after recognition of dependence risk)
	\| mechanism = <vote slug="ultracet-mech-claim">Tramadol is a weak μ-opioid receptor agonist whose major analgesic activity comes from CYP2D6-mediated bioactivation to O-desmethyltramadol (M1), with substantial additional contribution from serotonin and norepinephrine reuptake inhibition; the dual mechanism resembles SNRI antidepressants in some respects.</vote> '''Serotonin syndrome risk''' with SSRIs, SNRIs, MAOIs, and other serotonergic agents. Seizure risk especially at high doses, in patients with epilepsy, or with concurrent serotonergic ~~medications~~. CYP2D6 PGx affects efficacy through M1 conversion<ref name="cpic-opioid-cyp2d6">CPIC Guideline for CYP2D6, OPRM1, and COMT and Opioid Use, 2021. https://cpicpgx.org/guidelines/cpic-guideline-for-codeine-and-cyp2d6/</ref>.		\| mechanism = <vote slug="ultracet-mech-claim">Tramadol is a weak μ-opioid receptor agonist whose major analgesic activity comes from CYP2D6-mediated bioactivation to O-desmethyltramadol (M1), with substantial additional contribution from serotonin and norepinephrine reuptake inhibition; the dual mechanism resembles SNRI antidepressants in some respects.</vote> '''Serotonin syndrome risk''' with SSRIs, SNRIs, MAOIs, and other serotonergic agents. Seizure risk especially at high doses, in patients with epilepsy, or with concurrent serotonergic medicines. CYP2D6 PGx affects efficacy through M1 conversion<ref name="cpic-opioid-cyp2d6">CPIC Guideline for CYP2D6, OPRM1, and COMT and Opioid Use, 2021. https://cpicpgx.org/guidelines/cpic-guideline-for-codeine-and-cyp2d6/</ref>.
	}}		}}

	== References ==		== References ==
	<references />		<references />

MDElliottMD: parser-claude batch MedTemplate pre-fill, mind-medicine combination

2026-05-23T04:44:11Z

parser-claude batch MedTemplate pre-fill, mind-medicine combination

New page

{{MedTemplate
| generic = Tramadol / Acetaminophen
| brand = Ultracet, Tramacet
| structure =
| classes = [[:Category:Opioid_analgesics|Opioid analgesic (tramadol, atypical)]], [[:Category:Non-opioid_analgesics|Non-opioid analgesic (acetaminophen)]], [[:Category:Schedule_IV_controlled_substances|Schedule IV controlled substance]], [[:Category:Fixed-dose_combinations|Fixed-dose combination]], [[:Category:SNRIs|Serotonin-norepinephrine reuptake inhibitor (tramadol secondary action)]]
| uses = <vote slug="moderate-acute-pain-use">Moderate to moderately severe acute pain (short-term, ≤5 days per label)</vote>
| starting_dose = 2 tablets (75 mg tramadol / 650 mg acetaminophen) PO every 4-6 hours as needed; maximum 8 tablets/day for ≤5 days
| preparations = Tramadol/acetaminophen 37.5/325 mg tablets
| fda_max = 8 tablets/d (300 mg tramadol / 2600 mg acetaminophen); 5-day duration limit per label
| pill_id =
| routes = Oral
| onset = 30-60 minutes
| duration = 4-6 hours
| halflife = Tramadol ~5-7 hours (M1 metabolite ~9 hours); acetaminophen 1-3 hours<ref name="ultracet-label">FDA Prescribing Information, Ultracet (tramadol HCl / acetaminophen), Janssen, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021123s032lbl.pdf</ref>
| bioavailability = Tramadol ~75% (oral); acetaminophen 85-98%<ref name="ultracet-label" />
| pregnancy = Avoid; neonatal opioid withdrawal documented.{{citation needed}}
| legal = [[USLegal:Schedule IV|Schedule IV controlled substance]] in US (tramadol was reclassified from non-controlled to Schedule IV in 2014 after recognition of dependence risk)
| mechanism = <vote slug="ultracet-mech-claim">Tramadol is a weak μ-opioid receptor agonist whose major analgesic activity comes from CYP2D6-mediated bioactivation to O-desmethyltramadol (M1), with substantial additional contribution from serotonin and norepinephrine reuptake inhibition; the dual mechanism resembles SNRI antidepressants in some respects.</vote> '''Serotonin syndrome risk''' with SSRIs, SNRIs, MAOIs, and other serotonergic agents. Seizure risk especially at high doses, in patients with epilepsy, or with concurrent serotonergic medications. CYP2D6 PGx affects efficacy through M1 conversion<ref name="cpic-opioid-cyp2d6">CPIC Guideline for CYP2D6, OPRM1, and COMT and Opioid Use, 2021. https://cpicpgx.org/guidelines/cpic-guideline-for-codeine-and-cyp2d6/</ref>.
}}

== References ==
<references />